Vor Ort
Merkzettel Warenkorb
Produktbild: A Guide to Early Drug Discovery
Vorbesteller Neu

A Guide to Early Drug Discovery Building Confidence in Drug Candidates

148,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

31.10.2026

Abbildungen

Worked examples or Exercises

Herausgeber

Gary C. Starling + weitere

Verlag

Cambridge Academic

Sprache

Englisch

ISBN

978-1-00-930046-9

Beschreibung

Portrait

Dr Mohammed Shahid is a pharmacologist and drug discovery scientist with nearly forty years of experience in pharmaceutical R&D at Organon, Schering-Plough, Merck, Orion Pharma, and Pheno Therapeutics. Currently, he is Director of MS4Pharma Ltd, an independent consultancy, and brings deep expertise in application of innovation across different therapeutic areas.

Dr James Baker is Head of DMPK at Blueprint Medicines, with over twenty-five years in drug discovery at Merck, Pfizer, Organon, and Schering-Plough. He is a past Chair of the New England Drug Metabolism Discussion Group and serves on the IQ Consortium's Translational ADME Leadership Group.

Dr Gary Starling is an immunologist with over thirty years in biopharmaceutical research, focusing on antibody-based therapeutics. He has held senior roles at Bristol Myers Squibb, CuraGen, Abbott, and Merck, and currently serves as Senior Advisor, Oncology Research at Astellas Pharma in California.

Dr Jayashree Aiyar is a molecular pharmacologist with over thirty years of experience leading drug discovery programs at AstraZeneca, Merck, Ambrx, and Theravance. She holds a PhD in Immunology from AIIMS, New Delhi, and is currently Chief Scientific Officer, driving R&D strategy and academia-industry collaboration.

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

31.10.2026

Abbildungen

Worked examples or Exercises

Herausgeber

Verlag

Cambridge Academic

Sprache

Englisch

ISBN

978-1-00-930046-9

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: A Guide to Early Drug Discovery

  • Introduction Mohammed Shahid; Preface; Modern drug discovery: factors shaping the current and future landscape Mohammed Shahid, James Baker and Jayashree Aiyar; Part I. Drug Target: Linking Fundamental Biology to Disease Mohammed Shahid, M. Emani, G. Starling, J. Aiyar: 1. Target identification and preclinical validation Kati Räsänen; 2. The impact of translational biomarkers on drug discovery and development Donald Apanovitch and William Cairns; 3. Translational animal models: lessons from psychiatric disease Jennifer Fletcher, Ben Grayson and Michael Harte; 4. Quantitative systems biology and pharmacology Jess Wu, Tomoki Yoneyama and Dean BottinoI; 5. Flourishing landscape of therapeutic categories: how to select and characterize drug modalities Jerome Hochman; Part II. Discovery and Early Development of Small Molecule Drug Candidates Mohammed Shahid and J. Aiyar: 6. From classical to innovative screening approaches: bridging the gap to efficiently discover chemical starting points Benjamin Bader, Volker Badock, Jörg Weiske, Martina Schäfer, Anselm Schneider, Vera Pütter, Simon Holton, Martin Lange and Holger Steuber; 7. New developments in medicinal chemistry approaches for drug candidate identification Leena Otsomaa and Olli Tormakangas; 8. Application and impact of generative artificial intelligence in early drug discovery Cheng Fang and Torsten Herbertz; Part III. Discovery and Early Development of Biologics G. Starling and Emani; 9. Advances in therapeutic antibody discovery: from in vivo to in vitro and beyond Lei Chen, Jane Seagal and Chung-Ming Hsieh; 10. Creation of biologics therapeutics with drug-like properties - design, optimization, and developability Laurence Fayadat-Dilman; 11. Next generation biologics - multi-specifics, antibody drug conjugates and drugging difficult targets Rebecca Chen, Zhiping Jiang, Haili Zhang, Fan Yang and Javier Chaparro-Riggers; 12. Living cells as therapeutics Gary Starling; Part IV. Preclinical Adme and Safety J. Baker: 13. The evolution of small molecule pk optimisation Simon Taylor, Barry Jones and James Baker; 14. Therapeutic proteins - pk design considerations Sher Karki, Nicole Rodriguez, Panida Lertkiatmongkol and Shelley Sims Belouski; 15. Gene therapy - what is the role of DMPK in this modality? Guanrong Huang, Shobha Purushothama and Stephen Wang; 16. The application of translational PKPD modelling in drug discovery James W. T. Yates; 17. Pharmaceutical development across modalities in drug discovery Courtney David, Jing Ling and Olivier Mozziconacci; 18. Approaches to identify safe drugs across modalities Claudette L. Fuller, Lisa M. Plitnick and Alan H. Stokes; Part V. External Innovation Shahid Mohammed and Jayashree Aiyer: 19. Drug discovery and the benefit of public private partnerships, a solution to drive innovation in women's health? Marcel van Duin; 20. Governmental initiatives to boost progress and industry output: impact of the innovative medicines initiative Elisabetta Vaudano and Hugh Laverty; 21. Inventions to application: power of knowledge transfer Jack Findlay and Anji Milleri; 22. Harnessing innovation and delivering added value: view from the biotech venture capital world Sham Nikan and Narayanan 'Suri' Surendranb; 23. The evolution and future prospects of the contract research organisation (CRO) sector Brian McFerran and Stuart McElroy; Glossary and Index.